Intravacc announces the publication of a GMP process for a semi-synthetic Shigella glycoconjugate vaccine candidate from Institut Pasteur

Intravacc announces the publication of a GMP process for a semi-synthetic Shigella glycoconjugate vaccine candidate from the Institut Pasteur Bilthoven, the Netherlands, and Paris, France, 22 March 2022 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced the publication of a GMP (Good Manufacturing Practices) manufacturing and…